{"created":"2023-05-15T12:17:06.037036+00:00","id":788,"links":{},"metadata":{"_buckets":{"deposit":"0267a64b-9126-4827-bc95-8f5f6ca971a8"},"_deposit":{"created_by":8,"id":"788","owners":[8],"pid":{"revision_id":0,"type":"depid","value":"788"},"status":"published"},"_oai":{"id":"oai:aino.repo.nii.ac.jp:00000788","sets":["7:74"]},"author_link":["2542","2775"],"control_number":"788","item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-03-31","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicNumberOfPages":"15","bibliographicPageEnd":"87","bibliographicPageStart":"73","bibliographicVolumeNumber":"16","bibliographic_titles":[{"bibliographic_title":"AINO JOURNAL","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The era of pharmacotherapy in Japan was opened with chlorpromazine developed in 1955. Since then Japanese Pharmas were quite energetic in developing new antipsychotics with little modification. Availability of so many antipsychotics may have led Japanese psychiatric service too much relied on antipsychotics. The era of the second generation antipsychotics (SGA) in Japan began with introduction of risperidone in 1996. Since then Japanese Pharmas produced SGAs such as perospirone, blonanserin, and aripiprzol, some of which have attained a great success in the world.\nMore and more SGAs will be introduced to Japanese market including brexpirazol, and lurasidone. Japanese psychiatrists are expected to be experts in utilizing these new SGAs, but it should be kept in mind of all psychiatrists that psychiatric service can be attained through the good practice in cooperation with the patients and their families and the role of antipsychotics should be re-evaluated considering the right direction in developing better clinical service to psychiatric patients.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"AINO UNIVERSITY","subitem_publisher_language":"en"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1348-480X","subitem_source_identifier_type":"PISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"Takeda, Masatoshi","creatorNameLang":"en"}],"familyNames":[{"familyName":"Takeda","familyNameLang":"en"}],"givenNames":[{"givenName":"Masatoshi","givenNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2542","nameIdentifierScheme":"WEKO"}]},{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"Mizoguchi, Yukie","creatorNameLang":"en"}],"familyNames":[{"familyName":"Mizoguchi","familyNameLang":"en"}],"givenNames":[{"givenName":"Yukie","givenNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2775","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2023-04-27"}],"displaytype":"detail","filename":"Development of antipsychotics in Japan.pdf","filesize":[{"value":"1.4 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"Development of antipsychotics in Japan","url":"https://aino.repo.nii.ac.jp/record/788/files/Development of antipsychotics in Japan.pdf"},"version_id":"43e5540c-721d-49a6-98fd-51e0b2968adf"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"antipsychotics","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"first generation antipsychotics (FGA)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"second generation antipsychotics (SGA)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"serotomin-dopamine antagonist (SDA)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Japanese Pharma","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Development of antipsychotics in Japan","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Development of antipsychotics in Japan","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"8","path":["74"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2022-07-13"},"publish_date":"2022-07-13","publish_status":"0","recid":"788","relation_version_is_last":true,"title":["Development of antipsychotics in Japan"],"weko_creator_id":"8","weko_shared_id":8},"updated":"2025-09-11T04:12:12.577040+00:00"}